Indiana Headlines

Creative Biolabs Upgrades Conjugate Sites Analysis Service for Antibody-drug Conjugate Development

 Breaking News
  • No posts were found

Creative Biolabs Upgrades Conjugate Sites Analysis Service for Antibody-drug Conjugate Development

November 28
01:18 2019

New York, USA – Aiming at providing the most complete antibody-drug conjugate (ADC) development services, Creative Biolabs, the undoubted pioneer in the ADC field, upgrades conjugate sites analysis services for both academic and industrial clients all over the world.

As one of the most popular immunotherapies that have been proved efficient methods, antibody-drug conjugates that consist of monoclonal antibody, payload, and chemical linker present excellent efficacy on the treatment of leukemia and solid tumors, bringing novel insights for researchers. The payload drug plays a significant role to enable a variety of conjugation sites. In order to assist global clients with the identification of conjugate sites in their ADC projects, rich-experienced scientists at Creative Biolabs are capable of providing highly individualized ADC conjugate sites analysis services in terms of specific requirements.

Through the support from Creative Biolabs, clients can receive a detailed map of conjugated drug-linker locations via mass spectroscopy along with information regarding the physical attachment of the unreacted drug-linker on the antibody, featuring comprehensive sequence coverage and accurate peptide identification. Based on the peptide mapping using highly sensitive and accurate LC-MS/MS, Creative Biolabs can conduct the most comprehensive conjugate sites analysis services ranging from sample preparation to data analysis.

1 Sample preparation

At this stage, technicians firstly treat the ADC samples with PNGase F to remove the N-glycans to reduce the complexity of the ADC molecules and reduce the special hindrance for enzymatic degradation, which called de-glycosylation. Then, through reduction and alkylation, the de-glycosylated ADC samples are further reduced by DTT and then blocked using Iodoacetamide to facilitate digestion.

2 Protease digestion

The blocked ADC protein fragments are cleaved into smaller peptides by two or more proteases to increase the sequence coverage. Creative Biolabs offers a verity of proteases, including trypsin, chymotrypsin, Lys-C, Glu-C, Asp-N, Arg-C.

3 LC/MS analysis

Both standard flow UV LC-MS/MS system to analyze large sample amounts (>20 µg per analysis) and nano-flow LC-MS/MS that is suitable for small quantity (in the low µg range) analysis are available at Creative Biolabs. Its cutting-edge platform is equipped with various MS instrument, including QTOF, MALDI MS/MS, and Tripple TOF to analyze versatile samples.

4 Data analysis

For the sake of a detailed report, the specialists at Creative biolabs will analyze the mapping data from four aspects, which are the amino acid sequences of heavy chain and light chain, verification of the chemical nature of the conjugate sites (Lys, Cys…), identification of conjugated vs unconjugated amino acids, and quantification of conjugated vs unconjugated amino acids.

After years of accumulation at the ADC field, Ph.D. level scientists from Creative Biolabs have established a one-stop system for ADC development projects. More information can be found at https://www.creative-biolabs.com/adc.

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.creative-biolabs.com/adc